Dr. Manish Monga named medical director of WVU Clinical Trials Research
MORGANTOWN, W.Va. – Manish Monga, M.D., has joined the WVU Mary Babb Randolph Cancer Center as the medical director of the Clinical Trials Research Unit (CTRU), which offers the latest treatment alternatives for cancer patients.
“We are thrilled to recruit such an experienced oncology physician as Dr. Monga,” Scot C. Remick, M.D., director of the Cancer Center, said. “His clinical skills are beyond reproach. Equally important, given his former training at the National Cancer Institute in drug development, we look forward to his leadership to grow our early phase cancer clinical trials program for our patients.”
Prior to joining the staff at WVU, Monga was director of medical oncology services at the Schiffler Cancer Center at Wheeling Hospital.
“Over the past 10 years, Dr. Monga has successfully built an outstanding oncology program at Wheeling Hospital, which has one of the most active clinical trial programs in the region,” Jame Abraham, M.D., chief of Hematology/Oncology at WVU, said. “He will help strengthen our early drug development program.”
“The state of West Virginia provides unique challenges for cancer care due to its population demographics and healthcare disparities,” Monga said. “West Virginia University and the Mary Babb Randolph Cancer Center are leading the state in meeting those challenges, and my role as a clinical researcher will be to further that goal.”
Monga’s research interests include thoracic malignancies and melanoma. He also treats head and neck cancer, melanoma and lung cancer patients.
A 27-year lymphoma cancer survivor, Monga is interested in cancer survivorship issues and the long-term effects of cancer therapy. “Because of my diagnosis, I can identify with patients and what they are going through during treatment,” he said.
In 2011 he was ranked in the top 1 percent nationally in patient safety for cancer care physicians, by CareChex, a medical quality rating service of the Delta Group, the nation’s largest privately-held healthcare information service company. CareChex provides clinical, financial and patient satisfaction findings to consumers, providers and purchasers of U.S. medical care. CareChex also provides a comprehensive evaluation of all components of medical quality outcomes of care.
Monga attended medical school in his native country of India, where he developed an interest in research and care for underserved individuals. After completing a residency in internal medicine at Cook County Hospital in Chicago, he became a fellow at the National Cancer Institute (NCI) in Bethesda, Md. While at the NCI, Monga pursued special research in phase I clinical trial drug development.
He is board-certified in medical oncology.
To make an appointment or refer a patient to Dr. Monga call 304-598-4500.
“We are thrilled to recruit such an experienced oncology physician as Dr. Monga,” Scot C. Remick, M.D., director of the Cancer Center, said. “His clinical skills are beyond reproach. Equally important, given his former training at the National Cancer Institute in drug development, we look forward to his leadership to grow our early phase cancer clinical trials program for our patients.”
Prior to joining the staff at WVU, Monga was director of medical oncology services at the Schiffler Cancer Center at Wheeling Hospital.
“Over the past 10 years, Dr. Monga has successfully built an outstanding oncology program at Wheeling Hospital, which has one of the most active clinical trial programs in the region,” Jame Abraham, M.D., chief of Hematology/Oncology at WVU, said. “He will help strengthen our early drug development program.”
“The state of West Virginia provides unique challenges for cancer care due to its population demographics and healthcare disparities,” Monga said. “West Virginia University and the Mary Babb Randolph Cancer Center are leading the state in meeting those challenges, and my role as a clinical researcher will be to further that goal.”
Monga’s research interests include thoracic malignancies and melanoma. He also treats head and neck cancer, melanoma and lung cancer patients.
A 27-year lymphoma cancer survivor, Monga is interested in cancer survivorship issues and the long-term effects of cancer therapy. “Because of my diagnosis, I can identify with patients and what they are going through during treatment,” he said.
In 2011 he was ranked in the top 1 percent nationally in patient safety for cancer care physicians, by CareChex, a medical quality rating service of the Delta Group, the nation’s largest privately-held healthcare information service company. CareChex provides clinical, financial and patient satisfaction findings to consumers, providers and purchasers of U.S. medical care. CareChex also provides a comprehensive evaluation of all components of medical quality outcomes of care.
Monga attended medical school in his native country of India, where he developed an interest in research and care for underserved individuals. After completing a residency in internal medicine at Cook County Hospital in Chicago, he became a fellow at the National Cancer Institute (NCI) in Bethesda, Md. While at the NCI, Monga pursued special research in phase I clinical trial drug development.
He is board-certified in medical oncology.
To make an appointment or refer a patient to Dr. Monga call 304-598-4500.